CarolLaceyPA

PubMed

• 7 citations
  GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report.
  Sapna Pradyuman Patel, Dae Won Kim, Carol Lacey, Patrick Hwu
  Medicine. 2016-01-01
• 24 citations
  Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report
  Isabella C. Glitza, Cara Haymaker, Chantale Bernatchez, Luis M Vence, Michelle Rohlfs
  Cancer Immunology Research. 2015-11-01
• 179 citations
  IL-2 therapy promotes suppressive ICOS + Treg expansion in melanoma patients
  Geok Choo Sim, Natalia Martin-Orozco, Lei Jin, Yan Yang, Sheng Wu
  The Journal of Clinical Investigation. 2014-01-02

Journal Articles

• Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results  
  Isabella Glitza, et al, Nature Medicine, 3/30/2023
• Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2  
  Isabella Glitza, et al., ESMO, 1/1/2019
• THERAPEUTIC OUTCOMES OF INTRATHECAL INTERLEUKIN-2 IN METASTATIC MELANOMA PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD)  
  Isabella Glitza, et al, Neuro-Oncology, Volume 17, Issue suppl_5, 1 November 2015, Page v108,, 11/9/2015
• Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, GleevecTM)  
  Doina Ivan, et al., Journal of Cutaneous PathologyVolume 33, Issue 4, 3/29/2006
• Join now to see all

Abstracts/Posters

• BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma.
  M. Rohlfs et al, Journal of Clinical Oncology 2016 34:15_suppl, 9548-9548, 5/15/2016